Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Aug 13, 2026
Silo Pharma, Inc. (SILO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $832,829.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-832,829
+30.8% vs year-ago quarter
Operating cash flow
$-781,861
+39.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.76
+73.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.59M
-83.1% vs year-ago quarter
Net cash
—
Operating margin
-8250.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SILO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Sarasota, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1514183
- Former names
- Uppercut Brands, Inc. (until Aug 14, 2020); Point Capital, Inc. (until May 14, 2019); Gold Swap Inc (until Jan 7, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $18,026 | $18,026 | $18,025 | $18,025 |
| Operating income | -$928,949 | -$1.6M | -$786,524 | -$1.2M | -$1.2M |
| Net income | -$832,829 | -$1.6M | -$881,530 | -$1.1M | -$1.2M |
| Diluted EPS | -$0.76 | -$0.12 | -$0.07 | -$0.12 | -$2.88 |
| Operating cash flow | -$781,861 | -$822,623 | -$780,278 | -$955,493 | -$1.3M |
| Total assets | $6.0M | $7.0M | $7.6M | $6.4M | $6.7M |
| Total liabilities | $1.1M | $1.3M | $1.3M | $1.4M | $1.7M |
| Stockholders' equity | $4.9M | $5.7M | $6.3M | $5.0M | $4.9M |
| Cash and investments | $5.2M | $6.0M | $6.9M | $5.9M | $6.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 19, 2026 | Aug 18, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 13, 2026 | Jul 9, 2026 |
All 378 Silo Pharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.